A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Clinical trial NCT03187262 · COMPLETED
Trial details
- NCT number
- NCT03187262
- Sponsor
- Dana-Farber Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-27
- Primary completion
- 2021-01-31
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.